Arctoris has announced the launch of its Biophysics Centre of Excellence, a major expansion of infrastructure, expertise, and strategic partnerships designed to meet the growing demand for high-quality experimental data in AI-driven drug discovery. As AI and generative molecular design accelerate hypothesis generation, a key bottleneck has emerged: experimental validation capacity has not kept pace.…

Arctoris contributed to research advancing a fully autonomous, closed-loop molecular discovery platform, demonstrated through a case study targeting Janus kinase (JAK) proteins, key therapeutic targets in cancer and inflammatory diseases. JAK proteins play a central role in cellular signalling pathways that regulate immune response, cell proliferation, and survival, making them important targets across oncology and…

Arctoris collaborated with researchers at the University of Cambridge and King’s College London on a study demonstrating how artificial intelligence can identify novel drug combinations capable of killing cancer cells. The research explored whether AI systems could move beyond data analysis to actively generate new therapeutic hypotheses. Using advanced computational approaches, the team identified combinations…

Arctoris was featured in Drug Discovery World (DDW) in an article exploring how the integration of end-to-end laboratory automation and artificial intelligence is transforming drug discovery. The piece highlights the limitations of traditional drug discovery approaches, which are often slow, costly, and reliant on manual experimentation. By contrast, combining automation with AI enables a more…

Arctoris was featured in Forbes as part of a wider exploration of how robotics and artificial intelligence are converging to transform drug discovery. The article set the scene for a rapidly growing industry, with robotics in pharma expected to grow from a $2.05 billion sector in 2019 to $4.87 billion by 2023, driven by the…

Arctoris was featured in Forbes following its early recognition as a trailblazer in a brand new field: the cloud lab for cancer research. The article explored how Arctoris was reimagining the traditional molecular biology laboratory, where researchers typically spend the majority of their day on manual, repetitive tasks such as pipetting and labelling, leaving little…

What if AI could design a brand-new protein, from scratch, to tackle heart disease? That’s no longer science fiction. In a breakthrough collaboration, 310.ai and Arctoris have validated the first de novo protein from 310’s MP4 platform that binds ATP – a critical step towards restoring energy in failing hearts. Targeting the Root Cause of…

Arctoris was featured in Drug Discovery World (DDW), one of the industry’s leading publications, following the launch of Ulysses®, our fully automated drug discovery platform designed to address fundamental challenges in conventional drug discovery by removing human error and variability, and delivering reliable, reproducible, and fully auditable datasets. The feature highlights how Ulysses® was built…

Arctoris was featured in First Word Pharma following the announcement of a technology partnership with Insilico Medicine, a leading AI-driven biotechnology company, to jointly discover and profile new therapeutics against COVID-19. The collaboration brought together two highly complementary capabilities: Insilico Medicine’s AI-guided drug discovery, spanning target identification and generative chemistry, and Arctoris’ robotic platform for…